Jamie Manning
| Position | PhD Student |
|---|---|
| Department | Department of Pharmacology and Toxicology |
| Qualifications | BSc(Hons) in Pharmacology |
| Research summary | B-Arrestin-mediated cannabinoid receptor signalling |
Research
My PhD project investigates factors that influence the recruitment of B-arrestin-1 and -2 to the cannabinoid receptor such as receptor phosphorylation and other interacting proteins. Subsequent goals involve identifying cell signalling downstream of B-arrestin recruitment, and the influence of different categories of cannabinoid ligands (endogenous, synthetic, plant-derived) on this signalling.
Publications
Kevin, R. C., Anderson, L., McGregor, I. S., Boyd, R., Manning, J. J., Glass, M., … Banister, S. D. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10, 595. doi: 10.3389/fphar.2019.00595
Finlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., … Glass, M. (2019). Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chemical Neuroscience, 10, 4350-4360. doi: 10.1021/acschemneuro.9b00429
Cooper, A. G., Oyagawa, C. R. M., Manning, J. J., Singh, S., Hook, S., Grimsey, N. L., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2018). Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 9(12), 2055-2067. doi: 10.1039/c8md00448j
Journal - Research Article
Kevin, R. C., Anderson, L., McGregor, I. S., Boyd, R., Manning, J. J., Glass, M., … Banister, S. D. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10, 595. doi: 10.3389/fphar.2019.00595
Finlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., … Glass, M. (2019). Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chemical Neuroscience, 10, 4350-4360. doi: 10.1021/acschemneuro.9b00429
Cooper, A. G., Oyagawa, C. R. M., Manning, J. J., Singh, S., Hook, S., Grimsey, N. L., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2018). Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 9(12), 2055-2067. doi: 10.1039/c8md00448j
